Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Zeng Y.Whole-process management for patients with hepatocellular carcinoma.Chinese Journal of Practical Surgery2021;41:343-7.

[3] Li Q.Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 edition).Chinese Journal of Digestive Surgery2023;22:824-42.

[4] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[5] National Health Commission of the People's Republic of ChinaStandardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition).Chinese Journal of Digestive Surgery2022;21:143-68.

[6] Wu JY,Bai YN.Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study.J Hepatocell Carcinoma2021;8:1233-40 PMCID:PMC8502053

[7] Xia Y,Qian X.Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.J Immunother Cancer2022;10:e004656 PMCID:PMC8981365

[8] Wei X,Zhang X.Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study.J Clin Oncol2019;37:2141-51 PMCID:PMC6698917

[9] Wei W,Li SH.Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.Cancer Commun2018;38:61 PMCID:PMC6235393

[10] Wang Z,Chen Y.Adjuvant transarterial chemoembolization for hbv-related hepatocellular carcinoma after resection: a randomized controlled study.Clin Cancer Res2018;24:2074-81

[11] Sun J,Shi J.Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: an open-label randomized controlled trial.Radiother Oncol2019;140:20-5

[12] Shi C,Geng L.Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: a randomised controlled trial.Eur J Cancer2022;166:176-84

[13] Chen B,Cheng SH.Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with HCC.Hepatology2021;74:2595-604 PMCID:PMC8672362

[14] Chen Q,Laurence AD.Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial.Gut2018;67:2006-16

[15] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[16] Finn RS,Ikeda M.IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).JCO2021;39:267-267

[17] Ren Z,Bai Y.ORIENT-32 study groupSintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol2021;22:977-90

[18] Qin S,Gu S.CARES-310 Study GroupCamrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.Lancet2023;402:1133-46

[19] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[20] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[21] Qin S,Gu S.Donafenib versus sorafenib in first-Line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial.J Clin Oncol2021;39:3002-11 PMCID:PMC8445562

[22] Kudo M.Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.Hepatobiliary Surg Nutr2022;11:592-6 PMCID:PMC9396100

[23] Qin S,Kudo M.RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.Future Oncol2019;15:1811-22

[24] Yau T,Finn RS.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol2022;23:77-90

[25] Qin S,Lim HY.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.J Clin Oncol2013;31:3501-8

[26] Bruix J,Merle P.RESORCE InvestigatorsRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[27] Qin S,Gu S.Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol2021;6:559-68

[28] Zhu AX,Yen CJ.REACH-2 study investigatorsRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019;20:282-96

[29] Abou-Alfa GK,Cheng AL.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63 PMCID:PMC7523244

[30] Qin S,Fang W.Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III Trial.J Clin Oncol2023;41:1434-43 PMCID:PMC9995104

[31] Qin S,Meng Z.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.Lancet Oncol2020;21:571-80

[32] Ren Z,Abou-Alfa GK.Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial.Liver Cancer2023;12:72-84 PMCID:PMC9982342

[33] Xu J,Gu S.Camrelizumab in combination with Apatinib in patients with advanced hepatocellular carcinoma (rescue): a nonrandomized, open-label, phase II trial.Clin Cancer Res2021;27:1003-11

[34] Chinese Association of Liver Cancer of Chinese Medical Doctor AssociationChinese Expert Consensus on Clinical Application of Molecular Targeted Drugs for Hepatocellular Carcinoma (2022 edition).National Medical Journal of China2022;102:2655-68.

[35] Chinese Association of Liver Cancer of Chinese Medical Doctor AssociationChinese expert consensus on immunotherapy for hepatocellular carcinoma (2021 Edition).National Medical Journal of China2021;101:3921-31.

[36] Viveiros P,Lewandowski RJ.Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC).Cancers2019;11:1085 PMCID:PMC6721343

[37] Llovet JM,Kulik L.Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2021;18:293-313

[38] Clinical Guidelines Committee of Chinese College of Interventionalists[Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)].Zhonghua Yi Xue Za Zhi2023;103:2674-94

[39] Zhang X,Wang M.Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.Oncotarget2017;8:29416-27 PMCID:PMC5438741

[40] Peng Z,Zhu B.Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH).J Clin Oncol2023;41:117-27

[41] Lyu N,Li JB.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1).J Clin Oncol2022;40:468-80

[42] Zhu XD,Shen YH.Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations.Liver Cancer2021;10:320-9 PMCID:PMC8339461

[43] Sun H,Gao Q.Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate-stage hepatocellular carcinoma (HCC): updated results of a phase II trial.JCO2023;41:e16220-e16220

[44] Committee of Liver Cancer of the Chinese Anti-Cancer AssociationChinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).Chinese Journal of Digestive Surgery2021;20:600-16.

[45] D'Avola D,Torre-Aláez M.The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma.J Hepatol2022;76:1185-98

[46] Pinato DJ,Allara E.The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.J Hepatol2017;66:338-46

[47] Huang G,He J.Chinese expert consensus on antiviral therapy for hepatitis B virus-related hepatocellular carcinoma (2023 edition).Chinese Hepatology2023;28:1-10.

[48] Vitale A,Iavarone M.HCC Special Interest Group of the Italian Association for the Study of the LiverPersonalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept.Lancet Oncol2023;24:e312-22